Who’s Going to World ADC London 2027
Mar 8–11, 2027 London, UK ~700 attendees Website
75 organizations and 43 speakers at World ADC London 2027, a ~700-person, mostly industry meeting of European antibody-drug conjugate developers. As of Oct 8, 2026.
| Organization | World ADC London 2027 Attendance |
|---|---|
AstraZeneca Cambridge, UK | |
Global pharmaceutical company whose ADCs include trastuzumab deruxtecan and datopotamab deruxtecan, co-developed with Daiichi Sankyo. | Talk Talk Aseptic Manufacturing of Antibody-Drug Conjugates – From Process Development to Validation Manufacturing & supply chain Talk Wed Mar 10 3:30pm A Scalable Lysine Bioconjugation Platform: Reducing Development Burden as Clinical Demand Scales Process & analytical developmentManufacturing & supply chain Also |
Iksuda Therapeutics Newcastle upon Tyne, UK | |
UK ADC developer with clinical programs and new payload classes, including a protein-alkylating payload. | Panel Tue Mar 9 9:30am Panel Tue Mar 9 5:00pm Talk Novel ADC Designs Drive Improved Clinical Outcomes ADC discovery Workshop Thu Mar 11 1:00pm |
Johnson & Johnson New Brunswick, NJ | |
Healthcare company that develops and markets medicines, including cancer therapies, through its Innovative Medicine business. | Also |
Pierre Fabre Castres, France | |
French pharmaceutical and dermo-cosmetics group developing oncology medicines, including antibody-drug conjugates. | Workshop Thu Mar 11 1:00pm Manufacturing Bispecifics, Dual Payloads & Novel Formats (DACs, AOD, POCs) at Scale Manufacturing & supply chain Also |
Roche Basel, Switzerland | |
Pharmaceutical and diagnostics company developing medicines in oncology, immunology, neuroscience and other areas. | Workshop Thu Mar 11 1:00pm |
VAR2 Pharmaceuticals Copenhagen, Denmark | |
Clinical-stage Danish biotech, spun out of the University of Copenhagen, developing therapies that target cancer-specific glycosaminoglycans. | Talk Also |
University of Michigan Ann Arbor, MI | |
Public research university in Ann Arbor, Michigan. | Panel Tue Mar 9 5:00pm Workshop Thu Mar 11 9:00am |
Oxford BioTherapeutics Oxford, UK | |
Oncology biotech discovering new cancer targets and developing antibody and ADC therapies, including the CD205-directed ADC OBT076. | Panel Tue Mar 9 9:30am Workshop Thu Mar 11 1:00pm |
Queen's University Belfast Belfast, UK | |
Public research university in Belfast, Northern Ireland. | Workshop Panel Tue Mar 9 5:00pm |
Amgen Thousand Oaks, CA | |
Global biotechnology company with marketed medicines in oncology, inflammation and cardiovascular disease, and research in protein therapeutics. | Talk Wed Mar 10 8:30am |
Swiss biotech developing antibody-drug conjugates, including multi-payload conjugates, with a linker that attaches payloads to unmodified antibodies. | Panel Tue Mar 9 9:30am |
Biopharmaceutical consultancy advising on drug discovery, preclinical and clinical development, and in-licensing of early-stage assets. | Talk Opportunities for Improving the Translational Safety of ADCs From NHPs to Humans Clinical development |
Boehringer Ingelheim Ingelheim, Germany | |
Family-owned German pharmaceutical company with human and animal health medicines and an oncology pipeline. | Panel Tue Mar 9 9:30am |
Clinical-stage biotech developing dual-payload ADCs, led by a HER2-targeted program, to counter tumor resistance. | Panel Tue Mar 9 5:00pm |
Cancer Research Center of Lyon Lyon, France | |
Cancer research center in Lyon run jointly by Inserm, CNRS, the University of Lyon and the Centre Léon Bérard. | Workshop Thu Mar 11 1:00pm |
Biotech developing antibody-drug conjugates against a new class of targets it calls TAPAs. | Talk TAPAs: A New Class of ADC Targets From Discovery to the Clinic Clinical development |
Innovent Biologics Suzhou, China | |
Chinese biopharmaceutical company with marketed antibody medicines and a pipeline that includes dual-payload ADCs. | Talk Tue Mar 9 6:00pm Over the Horizon: the Dual Payload Innovation ADC discovery |
Instantly find 20 buyers from companies at World ADC London 2027
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
When and where is World ADC London 2027?
17th World ADC London runs March 8–11, 2027, at Novotel London West in London, UK.
Where is the World ADC London 2027 program?
This guide lists every organization on the World ADC London 2027 program with its sessions; the full program is on the official website.
How do I register for World ADC London 2027?
Fees and registration are on the organizer's registration page.
What conference is this?
World ADC London is a European antibody–drug conjugate meeting, held for the 17th time March 8–11, 2027 in London. It brings together ADC discovery, preclinical and translational, clinical, process and analytical, and manufacturing teams from pharma and biotech with the CDMOs, CROs and suppliers that serve them: five tracks over two main days, a pre-conference seminar day and a post-conference workshop day.
What is in this guide?
Every organization we can place at World ADC London 2027 so far: the 43 speakers on the public speaker faculty rolled up to their companies and institutions (27 sessions named on the preliminary agenda, and 17 speakers whose sessions are not named yet), and the 40 partners from the public partner list with their tier, 15 of them Exhibition Partners — 75 organizations in one list. Speakers appear as job titles, never by name. The organizers publish no attendee list and no booth numbers.
How are organizations typed?
By the role an organization plays in ADC development: drug developers (large pharma and biotech), then the companies around them — CDMOs and CROs, instrument and equipment makers, reagent, material and model-system suppliers, software and data companies, and consultancies and other services — and academic, government and non-profit bodies. The track filters come from the track, seminar or workshop a session sits in.
How current is it?
Pulled from the public speaker faculty, the preliminary day-by-day agenda and the partner list on October 8, 2026, five months before the meeting. Most track sessions are not named yet: the organizers fill the agenda in the months before the meeting, and this guide will be refreshed as it does.
Browse World ADC London 2027 by
Organizations with their own page
45 organizations — every exhibitor and every organization with 2 or more presentations.
- Abzena
- Ajinomoto Bio-Pharma Services
- AstraZeneca
- AsymBio
- Axplora
- Beacon Intelligence
- Biocytogen
- BioPharmaSpec
- BSP Pharmaceuticals
- ChemExpress
- Cohance Lifesciences
- Cytiva
- FyoniBio
- Genovis
- Glycogene
- HUB Organoids
- Huida Biotech
- Iksuda Therapeutics
- ILC Dover
- Indena
- Intertek
- Leanbio
- LIDE Biotech
- Lonza
- MabPlex
- Merck KGaA
- Nona Biosciences
- Olon
- Oxford BioTherapeutics
- Pharmaron
- Piramal Pharma Solutions
- Procos
- ProJect Pharmaceutics
- Proveo
- Quality Assistance
- Queen's University Belfast
- Savillex
- Shilpa Pharma
- Simtra BioPharma Solutions
- SK pharmteco
- Sterling Pharma Solutions
- TAPI
- University of Michigan
- Veranova
- WuXi XDC
Not affiliated with or endorsed by World ADC or its organizers. Submit a correction